Trastuzumab Rezetecan

Approved

PPeking Union Medical College Hospital

Trastuzumab Rezetecan is one of 6 therapeutic programs targeting HER2 + Breast Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HER2 + Breast CancerRecruiting

Biliary Tract NeoplasmsRecruiting

HER2 + Breast CancerApproved

Recruiting

Biliary Tract NeoplasmsPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Biliary Tract Neoplasms

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

1 2

Lenvima

Eisai

Phase 2

1 3

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

2 4

Trastuzumab Rezetecan

PPeking Union Medical College Hospital

Approved

1 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Biliary Tract Neoplasms

NCT07670273

Q4 2031

ApprovedRecruiting

HER2 + Breast Cancer

NCT07600164

Clinical

Trials by Indication[1]

HER2 + Breast Cancer1 trial

Real-world Study of Pyrotinib-containing Regimens in First-line or Second-line Treatment of Advanced HER2-positive Breast Cancer

Recruiting·PPeking University People's Hospital·Approved·NCT07600164·500 enrolled

Biliary Tract Neoplasms1 trial

A Prospective, Open-label, Multicenter Phase II Clinical Study of Rikang Trastuzumab in Combination With Adebrelimab and Lenvatinib for First-line Treatment of HER2-positive or Low-expressing Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07670273·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Trastuzumab Rezetecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Trastuzumab Rezetecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: PPeking Union Medical College Hospital

Trastuzumab Rezetecan

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2031

Trials by Indication[1]

HER2 + Breast Cancer1 trial

Biliary Tract Neoplasms1 trial

References

Drug Info

Quick Facts

Related News